Healthy Skepticism Library item: 2496

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: Journal Article

Berkowitz BA, Sachs G.
Life Cycle of A Block Buster Drug: Discovery and Development of Omeprazole (PrilosecTM)
Mol Interv 2002 Feb; 2:(1):6-11
http://molinterv.aspetjournals.org/cgi/content/full/2/1/6, http://molinterv.aspetjournals.org/cgi/reprint/2/1/6,

Abstract:

Blockbuster drugs share a variety of common features, among which is the tendency to create entirely new markets. For example, an early “informed” estimate of the potential market size for the hypothetically “perfect” peptic ulcer drug was thirty-five million dollars. Based on current sales, however, we reckon this hypothesis to have underestimated the actual market demand for omeprazole (Prilosec™) by about 400-fold. Similarly, prior to the introduction of the “retired” blockbusters chlordiazepoxide and diazepam (Librium™ and Valium™), the market for “minor tranquilizers” in the treatment of anxiety and neurosis did not exist. Thus, once an emerging blockbuster seems to be therapeutically working, it is not unusual for diagnostic rates of the disease for which it is indicated and efficacious to actually increase. Top blockbuster drugs generally have or appear to have a high margin of safety.

Keywords:
*analysis United States industry perspective blockbusters omeprazole proton pump inhibitors chlordiazepoxide diazepam Astra AstraZeneca INFLUENCE OF PROMOTION: MEDICALIZATION OF PROBLEMS INFLUENCE OF PROMOTION: PRESCRIBING, DRUG USE PROMOTION IN SPECIFIC THERAPEUTIC AREAS: PSYCHIATRIC DISEASES